<DOC>
	<DOCNO>NCT00034177</DOCNO>
	<brief_summary>Phase IIA , multicenter , dose escalation study evaluate safety efficacy weekly S-8184 paclitaxel injectable emulsion second line treatment patient locally advance , metastatic , recurrent transitional cell carcinoma urothelium .</brief_summary>
	<brief_title>Safety Efficacy S-8184 Treatment Locally Advanced , Metastatic , Recurrent TCC Urothelium</brief_title>
	<detailed_description>The goal study determine objective response rate , determine time disease progression , duration response , survival , identify maximum tolerated weekly dose principal toxicity S-8184 patient population .</detailed_description>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologic diagnosis transitional cell carcinoma urothelium include renal pelvis , ureter , bladder , urethra Locally advance lymph node disease ( unresectable T34 , N+ , M0 ) ; metastatic ( T , N , MI ) ; locally recurrent disease follow initial definitive therapy One one prior systemic cytotoxic chemotherapy regimen ( note intravesical treatment include definition systemic cytotoxic chemotherapy ) Failure first line systemic chemotherapy platinumcontaining combination regimen consist MVAC cisplatin/gemcitabine cisplatin dose 60 mg/m2 high per cycle Adult ( 18 year age old ) patient Adequate hematologic function ( ANC great 1500 cells/mm3 platelet great 100,000/mm3 ) Serum creatinine le 2.0 mg/dL Total bilirubin le 1.5 mg/dL ; SGOT SGPT less 3 time upper limit institutional normal value ECOG performance status 0 2 Bidimensional measurable disease Patients sign IRB / Ethics Committee approve informed consent Life expectancy least 12 week Patient fully recover previous surgery ( least 4 week since major surgery ) Patient negative pregnancy test prior study entry premenopausal . ( Patients child bear potential must use medically effective form contraception treatment . ) Patients receive taxanecontaining preparation include Taxol ( paclitaxel ) Taxotere ( docetaxel ) Patients intracranial metastasis Females pregnant lactating Patients peripheral neuropathy NCICTC grade 2 great Patients receive widefield radiation , cytotoxic chemotherapy hormonal therapy within 4 week study entry ; mitomycin nitrosoureas within 6 week study entry Patients investigational agent within 4 week study entry Patients receive concurrent anticonvulsant know induce P450 isoenzymes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Locally Advanced , Metastatic , Recurrent Transitional Cell Carcinoma Urothelium</keyword>
</DOC>